Screener
BridgeBio Pharma BBIO Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from common stock issuances under ESPP | 5,466 | 3,237 |
| Proceeds from stock option exercises, net of repurchases | 22,589 | 2,521 |
| Transactions with noncontrolling interests | — | 800 |
| Repurchase of RSU shares to satisfy tax withholding | (4,074) | (1,776) |
| Net cash provided by financing activities | 549,892 | 60,328 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 309,878 | (140,502) |
| Cash, cash equivalents, and restricted cash at beginning of period | 572,140 | 683,244 |
| Cash, cash equivalents, and restricted cash at end of period | $882,018 | $542,742 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's net change in cash?
- BridgeBio Pharma (BBIO) reported net change in cash of $309.88M in Q1 2026.
- How has BridgeBio Pharma's net change in cash changed year-over-year?
- BridgeBio Pharma's net change in cash increased by 320.6% year-over-year, from -$140.5M to $309.88M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about BridgeBio Pharma's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude